Life Tech Capital

Life Tech Capital reiterated its Strong Buy on Oculus Innovative Sciences (NASDAQ: OCLS). At the same time, the rating agency left its price target on the company's stock unchanged at $4.75. On Thursday, OCLS added 5.38% to its value to finish the day at $1.37.

Life Tech Capital reiterated its Strong Buy rating on NeoStem (NYSE: NBS). At the same time, Life Tech left its price target on the company's stock unchanged at $4. In a research report published today, Life Tech states, "While R&D efforts are ongoing in the U.S., especially with their bone...

According to Life Tech Capital, Neoprobe (NYSE: NEOP) announced that it reached agreement with Platinum Montaur Life Sciences / Platinum Partners Value Arbitrage Fund to appoint Peter F. Drake, Ph.D. and Jess Emery Jones, M.D. to fill two current board vacancies with terms expiring at the 2012...

According to Life Tech Capital, NovaBay Pharmaceuticals (NYSE: NBY) presented a poster on the efficacy of NeutroPhase (NVC-101) solution with Pioneer Technology's (private) hydrophobic mesh Sorbact in healing chronic non-healing wounds at the 2011 Symposium on Advanced Wound Care (SAWC) in Dallas...

Life Tech Capital is out with a research report this afternoon, where it reiterates its Strong Speculative Buy rating on Peregrine Pharmaceuticals (NASDAQ: PPHM); it has a $5.00 price target on the stock. The LTC analysts cited a rebound in PPHM's contract manufacturing revenues as well as an...

Life Tech Capital is initiating coverage on Peregrine Pharmaceuticals (NASDAQ: PPHM) with a SPECULATIVE BUY rating. The analyst put a price target of $8.00 on the company. This is about 100% above where it trades currently. Phase I data for their drug Bavituximab at the American Association for...